论文部分内容阅读
5-Fu 是一种抗代谢药,其抗癌作用形式为直接掺入肿癌细胞RNA,并作为胸腺嘧啶核苷合成酶抑制剂而起作用。PALA 则是天门冬氨基甲酰移换酶抑制剂。理论上,当采用两药联合化疗时,由于细胞内嘧啶储存减少,将促进5-FU 进入细胞RNA。最近已在体外人体肿瘤细胞株的研究中观察到这一协同作用。本文估价了某些实体瘤患者对联合化疗的耐受力,确定了PALA 和5-FU 各自的剂量水平,并探讨接受联合化疗的肿瘤患者的周围血白细胞中5-FU 掺
5-Fu is an antimetabolite whose anticancer effect is in the form of direct incorporation into swollen cancer cell RNA and acts as a thymidine synthase inhibitor. PALA is an asparagine carbamoyl transferase inhibitor. In theory, when two drugs are used in combination with chemotherapy, 5-FU will be promoted into cellular RNA due to reduced intracellular pyrimidine storage. This synergy has recently been observed in studies of human tumor cell lines in vitro. This article assessed the tolerability of certain solid tumor patients for combination chemotherapy, determined the respective dose levels of PALA and 5-FU, and explored the involvement of 5-FU in peripheral blood leukocytes in tumor patients receiving combination chemotherapy.